ArticleMultiple sclerosis journal - experimental, translational and clinical
Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patients.
Jérôme De Seze et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.